Tr1X has won an FDA green light for a clinical trial testing TRX319, a cell therapy designed to restore immune balance, for ...
EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.
According to columnist Be, MS forces him to become a jack-of-all-trades in managing symptoms and daily tasks. There are benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback